Replies to post #14644 on GTC Biotherapeutics (fka GTCB)

[joethdo]

The fact that they haven't cut back to a bare bones cash hoarding company is because something is in the works. I wish I knew what it was but in this case perhaps no news is good news.

I think we'll see one more significant deal before February 2009 when we can hope for the approval of ATRYN in the US,

[oldberkeley]

Vin-

While I agree in principle that any business needs to watch costs, we all know that it takes money to make money.

I'd also be very worried about the negative, "this-is-our-last-desperate-gasp" signal that a cost-cutting announcement would send to the market. Whether it's one of the big boys like PFE or AMGN or a small fry like CEGE or MEMY, that announcement is usually followed by a prolonged drop in the PPS.

Perhaps MEMY would be the best example: announced layoffs and other cost-cutting measures,continued and even accelerated their PPS slide from the mid-0.20's to the current under 0.10.

I just don't know, it's a tough call. Damned if you do, damned if you don't.